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Objective To evaluate the relative cost-effectiveness in different sub-Saharan African settings of presumptive treatment, field-standard 
microscopy and rapid diagnostic tests (RDTs) to diagnose malaria.
Methods We used a decision tree model and probabilistic sensitivity analysis applied to outpatients presenting at rural health facilities 
with suspected malaria. Costs and effects encompassed those for both patients positive on RDT (assuming artemisinin-based combination 
therapy) and febrile patients negative on RDT (assuming antibiotic treatment). Interventions were defined as cost-effective if they 
were less costly and more effective or had an incremental cost per disability-adjusted life year averted of less than US$ 150. Data were 
drawn from published and unpublished sources, supplemented with expert opinion.
Findings RDTs were cost-effective compared with presumptive treatment up to high prevalences of Plasmodium falciparum 
parasitaemia. Decision-makers can be at least 50% confident of this result below 81% malaria prevalence, and 95% confident below 
62% prevalence, a level seldom exceeded in practice. RDTs were more than 50% likely to be cost-saving below 58% prevalence. 
Relative to microscopy, RDTs were more than 85% likely to be cost-effective across all prevalence levels, reflecting their expected 
better accuracy under real-life conditions. Results were robust to extensive sensitivity analysis. The cost-effectiveness of RDTs mainly 
reflected improved treatment and health outcomes for non-malarial febrile illness, plus savings in antimalarial drug costs. Results were 
dependent on the assumption that prescribers used test results to guide treatment decisions.
Conclusion RDTs have the potential to be cost-effective in most parts of sub-Saharan Africa. Appropriate management of malaria and 
non-malarial febrile illnesses is required to reap the full benefits of these tests.
Bulletin of the World Health Organization 2008;86:101–110.
Une traduction en français de ce résumé figure à la fin de l’article. Al final del artículo se facilita una traducción al español.
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Introduction
The introduction of high-cost antima-
larial drugs such as artemisinin-based 
combination therapy (ACT) is encour-
aging malaria-endemic countries in sub- 
Saharan Africa to reassess diagnostic 
practices. Traditional practice for out-
patients has been to treat presumptively 
for malaria based on a history of fever,1,2 
but a significant proportion of those 
treated may not have parasites (over 
50% in many settings) and hence waste 
a considerable amount of drugs.3–6 
Widespread prescription of chloroquine 
to patients not having malaria has been 
tolerated, partly because chloroquine is 
so cheap; however, ACT costs at least 10 
times more per treatment.7 Moreover, 
overdiagnosis of malaria implies under-
diagnosis and inappropriate treatment 
of non-malarial febrile illness: while a 
high proportion of such illnesses are 
self-limiting viral diseases, a significant 
minority, such as acute respiratory in-
fections or bacterial meningitis, are bac-
terial diseases and potentially fatal.8,9
WHO currently makes the tenta-
tive recommendation that parasite-based 
diagnosis should be used in all cases of 
suspected malaria with the possible ex-
ception of children in high-prevalence 
areas and certain other situations.10,11 
However, formal analyses have not es-
timated the epidemiological and eco-
nomic thresholds at which different 
diagnostic strategies are preferable. As 
microscopy is generally limited to larger 
clinics, rapid diagnostic tests (RDTs) for 
malaria could be considered for most 
patients in endemic regions. However, 
there is very little evidence to guide 
decision-makers on the relative cost-
effectiveness of presumptive treatment, 
RDTs and microscopy across epidemio-
logical settings.
The objective of this study is to use 
a decision tree model and probabilis-
tic sensitivity analysis to estimate the 
relative cost-effectiveness of RDTs, pre-
sumptive treatment and field standard 
microscopy in different epidemiological 
settings of sub-Saharan Africa where 
Plasmodium falciparum predominates.
Methods
We developed a decision tree that begins 
with ambulatory patients presenting 
with fever to health facilities in rural 
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sub-Saharan Africa (Fig. 1, Fig. 2, Fig. 3, 
Fig. 4), and proceeds through diagnosis 
and treatment to disease outcomes ac-
cording to the sensitivity and specificity 
of each diagnostic strategy, the patient’s 
age and malaria prevalence among pa-
tients. Typical facilities would include 
health centres and dispensaries staffed 
by nurses and perhaps clinical officers, 
and outpatient departments of district 
hospitals. Once given first-line treat-
ment, patients were assumed to face the 
same probabilities, health outcomes and 
costs regardless of diagnostic method. 
Parameter estimates for initial diagno-
sis and treatment were extracted from 
recently published data. Parameters 
describing treatment seeking patterns, 
costs for programme implementation 
and secondary treatment, and duration 
of disease were based mainly on those 
used in previous models.12,13 Expert 
opinion was relied on for probabilities 
of disease progression and mortality 
without appropriate treatment where 
reliable published data do not exist. 
Parameter values, sources, best estimates 
and probability distributions represent-
ing parameter uncertainty are available 
at: http://www.wpro.who.int/sites/rdt.
We assumed that health workers 
used the diagnostic test result in their 
clinical decision-making and that pa-
tients diagnosed positive for malaria 
received ACT and patients negative for 
malaria received an antibiotic such as 
amoxicillin. The proportion receiving 
antibiotics was varied in the sensitivity 
analysis. Best (most likely) estimates 
for drug efficacy were set at 85% for 
ACT in cases of malaria and 75% for 
antibiotics in bacterial disease. We as-
sumed that antibiotics were not effica-
cious for malaria or viral illness, and 
that antimalarials did not cure bacterial 
disease. We assumed no coinfection be-
tween malaria and bacterial infections. 
Presumptive treatment on the basis of 
a history of fever was assumed to have 
perfect sensitivity and zero specificity. 
For RDTs we assumed a test detecting 
histidine-rich protein-2 (HRP-2) spe-
cific for P. falciparum, as 90% of malaria 
in sub-Saharan Africa is P. falciparum, 
with best estimates for RDT sensitiv-
ity and specificity of 96% and 95%, 
respectively.14–19 Microscopic diagnosis 
was based on best standard practice of 
district-hospital and health-centre gen-
eral laboratories in sub-Saharan Africa, 
and assumed best estimates for sensi-
tivity and specificity of 82% and 85%, 
respectively.20,21 We made comparisons 
according to all possible levels of en-
demicity of malaria expressed in terms 
of prevalence of parasitaemia in febrile 
outpatients presenting at facilities.
The chances of a febrile episode 
being fatal are far higher if associated 
with HIV infection.9,22,23 Very high HIV 
prevalence would affect the decision 
tree parameters. To avoid a very complex 
decision tree structure, parameter values 
were set assuming that HIV prevalence 
was relatively low (about 10% of people 
five years old or over), which is typical 
outside southern Africa.
Rapid diagnostic test
(RDT) or
Presumptive treatment
(PT) or
Microscopy diagnosis
(M)
Malaria
P1
NMFI
1-PI
True positive - given ACT
RDT:P5 / PT:P6 / M:P7
False negative
RDT:1-P5 / PT:1-P6 / M:1-P7
Adheres to treatment
P11
Does not adhere (Node 3)
1-P11
P4
No treatment (Node 5)
1-P4
True negative
RDT:P8 / PT:P9 / M:P10
Cured (Node 1)
P13
1-P13
Given antibiotic - incorrect (Node 4)
False positive - given ACT -
incorrect drug
RDT:1-P8 / PT:1-P9 / M:1-P10
Given antibiotic
P4
No treatment
1-P4
P3
Viral infection (Node 13)
1-P3
Bacterial infection (Node 12)
Bacterial infection
P3
Viral infection (Node 9)
1-P3
P3
Viral infection (Node 11)
1-P3
Adheres to treatment
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Does not adhere (Node 8)
1-P12
Cured
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P16
Treatment
failure
(Node 7)
1-P16
Bacterial infection (Node 10)
Treatment failure (Node 2)
Fig. 1. Root decision tree applying to all diagnostic strategies, mapping diagnosis and subsequent events according to malaria and 
non-malarial febrile illness (NMFI)
ACT, artemisinin-based combination therapy.
We calculated the incremental cost 
in US dollars (2002 prices) of chang-
ing from one diagnostic approach to 
another from the joint perspective of 
providers and patients, using the ingre-
dients approach to calculate diagnosis 
costs, first-line drug costs and variable 
costs of second-line treatment.24 The 
costs of microscopy diagnosis included 
materials, staff time, training and super-
vision. RDT diagnosis included the unit 
cost of the test; diagnosis according to 
presumptive treatment was assumed to 
cost nothing. We assumed drug cost per 
adult dose to be US$ 1–2.4 for ACT 
and US$ 0.61–0.93 for antibiotics. 
We set the cost of RDT kits at US$ 
0.6–1 and that of microscopy at US$ 
0.32–1.27. Microscopy costs are depen-
dent on workload and were based on a 
range of 1000 to 6800 or more diagnoses 
per year. For simplicity we assumed that 
microscopy was used only for malaria 
diagnosis, not for other diseases. All 
other costs of first-line treatment were 
excluded as they were assumed to be the 
same across diagnostic strategies. We 
included variable costs to providers and 
patients of any second-line treatment 
(drugs, reagents, food), but excluded 
fixed costs (buildings, equipment, su-
pervision and most staff costs) as these 
would not change with numbers of 
patients. We assumed that unresolved 
uncomplicated malaria was treated with 
a second-line drug of the same price and 
efficacy as the first-line antimalarial. We 
assumed that secondary treatment for 
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Fig. 2. Malaria disease outcome tree after treatment failure, non-adherence, no first-line treatment or incorrect drug given to the 
patient after diagnosisa
Fully recovers
100%
Health centre outpatient
P19
Hospital outpatient
Fully recovers
Residual probability
Recovers with neurological sequelae
P29 & P30
Dies
P35Malaria disease progression
Severe disease
P23 & P24
Uncomplicated disease
1-P23 & 1-P24
Inpatient care
P21
No formal care
1-P21
Outpatient care
P22
No formal care
1-P22
Fully recovers
Residual probability
Recovers with neurological sequelae
P29 & P30
Dies
P33
Fully recovers
100%
P20
Fully recovers
100%
a  This tree arises from chance nodes 2, 3, 4 and 5 on the right hand side of the root tree (Fig. 1).
severe bacterial infection was an alter-
native antibiotic costing twice as much 
as first-line treatment. Costs associated 
with the management of neurological 
sequelae were excluded.
We measured health outcomes in 
terms of disability-adjusted life years 
(DALYs) averted, calculated according 
to the methods of Lopez et al. without 
age weights.25 We based life expectan-
cies on a west African life table with a 
life expectancy at birth of 50 years.
The causes of non-malarial febrile 
infection vary from region to region and 
encompass diseases such as acute respi-
ratory infections and bacterial menin-
gitis. For simplicity, disability weights 
and durations for uncomplicated and 
severe non-malarial febrile illnesses 
were assumed to be the same as those 
for malaria. We assumed that bacterial 
illness was more likely than malaria to 
become severe, but that only 5–15% 
of these infections had bacterial causes, 
with the rest being self-limiting viral 
infections.
We did probabilistic sensitivity 
analysis with Monte-Carlo simulations 
(Palisade @Risk add-in tool to Microsoft 
Excel), and cost and health outcomes 
were generated stochastically (10 000 
simulations). Policy-makers will wish to 
identify interventions that are less costly 
than the comparator and have better 
health outcomes, called dominant, and 
rule out those that are more costly and 
less effective, termed dominated. More 
costly and more effective interventions 
may be selected if they are thought to 
be good value for money. An interven-
tion was defined as cost-effective if it 
was dominant or had an incremental 
cost per DALY averted under US$ 150. 
The value of US$ 150 was chosen in the 
base case, to represent a decision-maker’s 
valuation of a healthy year of life. This 
was based on recommendations of the 
Ad Hoc Committee on Health Research 
Priorities, which stated that any inter-
vention costing less than US$ 150 per 
DALY averted should be considered at-
tractive in low-income countries.26
Additional sensitivity analyses were 
done by varying the parameter of inter-
est and malaria prevalence according to 
the ranges in Table 1. A full report of all 
results is available at: http://www.wpro.
who.int/sites/rdt, where customized 
results specific to local settings can be 
generated online using an interactive 
model.
Results
The incremental cost-effectiveness of 
RDTs and microscopy relative to pre-
sumptive treatment is shown in Fig. 5 
and Fig. 6. Each graph shows the prob-
ability that the strategy is cost-effective, 
dominant or dominated. These prob-
abilities can be interpreted as the level 
of risk associated with choosing one 
strategy over another. For example, at 
40% malaria prevalence, a rough aver-
age for sub-Saharan Africa,3 we can be 
over 97% certain that RDTs are cost-
effective compared with presumptive 
treatment, and over 70% certain that 
they are dominant. We provide results 
in terms of 50% risk and 95% risk as 
reference points, acknowledging that 
these thresholds tend to the extremes of 
risk acceptability and aversion.
A decision-maker can be 95% 
certain that RDTs are cost-effective rela-
tive to presumptive treatment at any 
prevalence below 62% (Fig. 5). There 
is 95% certainty that RDTs are not 
cost-effective above 90% prevalence. 
RDTs are cost-effective relative to pre-
sumptive treatment with 50% certainty 
even when prevalence is less than 81% 
(where the curve showing the probabil-
ity that RDTs are cost-effective crosses 
50% on the y-axis). RDTs are likely to 
be dominant with 50% certainty below 
58% malaria prevalence, and dominated 
above 87% malaria prevalence. At low 
levels of malaria prevalence there is mas-
sive overdiagnosis of malaria with pre-
sumptive treatment, and use of parasitic 
diagnosis results in large cost savings 
through avoided ACT prescriptions. At 
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Fig. 4. Disease outcome tree for all patients with viral illnessa
Fully recovers
100%
Health centre outpatient
P19
Hospital outpatient
Viral illness disease progression
Outpatient care
P22
No formal care
1-P22
Fully recovers
100%
P20
Fully recovers
100%
a  This tree arises from chance nodes 9, 11 and 13 on the right hand side of the root tree (Fig. 1).
very high malaria prevalences, presump-
tive treatment is cost-saving because 
the costs of diagnosis are avoided, and 
antimalarials are appropriate for nearly 
all patients.
Microscopy is likely to be cost-
effective relative to presumptive treat-
ment with 50% certainty when malaria 
prevalence is less than 67% (Fig. 6). 
This threshold drops to less than 41% 
prevalence when 95% certainty is re-
quired. Microscopy is not cost-effective 
(95% certainty) above 83% malaria 
prevalence. Microscopy is dominant 
with 50% certainty below 62% preva-
lence, and dominated above 85%.
RDTs are more than 85% likely to 
be cost-effective relative to microscopy 
across all levels of prevalence, and are 
more than 15% likely to be dominant 
(data not shown). Although RDTs have 
a higher initial unit cost than micros-
copy, fewer DALYs are incurred with 
RDTs as they have better sensitivity and 
specificity in an operational setting.
Sensitivity analysis
We tested the robustness of the cost-
effectiveness results extensively. Results 
are discussed here for the six parameters 
with the greatest impact (presented in 
Table 1 for prevalence rates of 5% and 
40%; further details can be found in fig-
ures available at: http://www.wpro.who.
int/sites/rdt). RDTs are consistently 
more attractive than microscopy in the 
base case analysis, and sensitivity analy-
ses has little effect on this comparison, 
so we restrict our discussion to RDTs 
relative to presumptive treatment.
Cost-effectiveness is sensitive to the 
cost of the initial diagnostic test, with 
RDTs becoming more cost-effective 
relative to presumptive treatment as their 
cost decreased. Results are presented in 
Fig. 7 with a cost-effectiveness prob-
ability plane, where RDT cost is varied 
along the y-axis, and malaria prevalence 
along the x-axis. For example, at 40% 
malaria prevalence, RDTs would be 
preferable to presumptive treatment 
with 50% certainty if an RDT cost less 
than US$ 4, and with 95% certainty 
with cost less than US$ 2.30 per test, 
well above the base case cost of US$ 
0.80.
The cost of an adult dose of ACT 
has a strong impact on the comparison 
of RDTs with presumptive treatment. 
RDTs become more cost-effective 
as ACT cost increases, although this 
trend is not uniform. At low malaria 
prevalence, everyone receives ACT 
Fig. 3. Bacterial disease outcome tree after treatment failure, non-adherence, no first-line treatment, or incorrect drug given to the 
patient after diagnosisa
Fully recovers
100%
Health centre outpatient
P19
Hospital outpatient
Fully recovers
Residual probability
Recovers with neurological sequelae
P31 & P32
Dies
P36
Bacterial illness
disease progression
Severe disease
P25 & P26
Uncomplicated disease
1-P25 & 1-P26
Inpatient care
P21
No formal care
1-P21
Outpatient care
P22
No formal care
1-P22
Fully recovers
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100%
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a  This tree arises from chance nodes 7, 8, 10 and 12 on the right hand side of the root tree (Fig. 1).
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Fig. 5. Probability that RDTs are cost-effective, dominant or dominated relative to 
presumptive treatment
RDT, rapid diagnostic test.
Table 1.  Sensitivity analysis: threshold level for parameters tested at which RDTs are preferable to presumptive treatment at 5% and 
40% malaria prevalence among febrile outpatients
Parameters tested Threshold level at which RDTs are preferable to presumptive treatment 
50% certainty 95% certainty
5% malaria 
prevalence
40% malaria 
prevalence
5% malaria 
prevalence
40% malaria 
prevalence
Cost of RDT
(US$ 0–4)
Any cost Any cost Any cost < US$ 2.30
Cost of an adult dose of ACT
(US$ 0–4)
Any cost Any cost Any cost > US$ 0.20
Adherence to ACT
(0–100%)
Any level Any level Any level Any level
Adherence to antibiotic
(0–100%)
Any level > 4% > 25% > 39%
Probability that non-malarial febrile illness is bacterial
(0–100%)
Any level > 4% > 20% > 23%
Probability that patient diagnosed negative for malaria 
receives antibiotica
(0–100%)
Any level Any level Any level > 23%
Probability that a patient with bacterial infection 
became severe
( 5 years: 10–25%)
(< 5 years: 20–40%)
Any level Any level Any level Any level
Proportion of presenting population 5 years old or over
(0–100%)
Any level Any level Any level Any level
Valuation of a DALY averted
(US$ 0–500)
Any value Any value > US$ 48 > US$ 70
ACT, artemisinin-based combination therapy; DALY, disability-adjusted life year; RDT, rapid diagnostic test.
a  When less than 100%, we assumed that antibiotics were randomly allocated to patients with non-malarial febrile illness.
under presumptive treatment, but the 
specificity of RDTs screens out 95% of 
patients with non-malarial febrile ill-
nesses, who receive antibiotics. At high 
prevalence, almost every patient receives 
ACT with both presumptive treatment 
and RDT diagnosis, so raising the cost 
of ACT has little impact on their rela-
tive cost-effectiveness. At 40% preva-
lence, RDTs are cost-effective with a 
high degree of certainty at any ACT 
cost above US$ 0.20, well below current 
ACT costs (US$ 1–2.40).7
RDTs become more cost-effective 
as adherence to antibiotics increases. 
Better adherence means that first-line 
therapy for patients diagnosed with 
non-malarial febrile infection is less 
likely to fail, but this has very little 
impact on costs because second-line 
treatment of bacterial infection is much 
less costly than that for malaria.
Whether the illness is bacterial has 
a strong impact on the cost-effectiveness 
of RDTs compared with presumptive 
treatment. As non-malarial febrile ill-
ness becomes more severe, it is more 
cost-effective to distinguish between 
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these diseases and malaria. At very high 
malaria prevalence, the probability that 
non-malarial febrile infection is bacte-
rial is irrelevant. At all levels of malaria 
prevalence commonly found in sub-
Saharan Africa, RDTs are cost-effective 
when more than 20% of non-malarial 
febrile patients have bacterial illnesses.
Whether a patient diagnosed as not 
having malaria receives an antibiotic has 
a moderate impact on the decision to 
change policy to RDTs from presump-
tive treatment. RDT cost-effectiveness 
improves as more patients with negative 
tests receive antibiotics because out-
comes of non-malarial febrile illnesses 
are less severe despite higher antibiotic 
costs. RDTs remain cost-effective below 
50% prevalence even when no patients 
testing negative for malaria receive an 
antibiotic, as RDTs are slightly less effec-
tive but much cheaper than presumptive 
treatment under these conditions.
Cost-effectiveness is sensitive to 
changes in the decision-maker’s valu-
ation of a healthy year of life (Fig. 8). 
Where malaria prevalence is low, RDTs 
are cost-effective at any value at 50% 
certainty, and above US$ 50 per DALY 
averted at 95% certainty. At high ma-
laria prevalence such as 65%, our con-
fidence that RDTs are cost-effective 
does not rise above 95% at any level of 
health gain valuation. This reflects the 
increased probability that presumptive 
treatment is dominant at high preva-
lence.
Fig. 6. Probability that field-standard microscopy is cost-effective, dominant or 
dominated relative to presumptive treatment
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Fig. 7. Probability planes showing sensitivity analysis of the cost-effectiveness of 
RDTs compared with presumptive treatment at different RDT costs
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Discussion
This study demonstrates that taking 
both antimalarial and antibiotic treat-
ments into account, RDTs are cost- 
effective compared with presumptive 
treatment up to high levels of P. falci-
parum malaria prevalence among pa-
tients with febrile illness presenting to 
rural health facilities.
Decision-makers can be at least 
50% confident of this result at less than 
80% malaria prevalence in febrile out-
patients, and 95% confident below 62% 
prevalence. In practice, the proportion 
of febrile outpatients who are parasi-
taemic seldom exceeds 60%, with most 
proportions being much lower, so this 
analysis suggests that RDTs are cost-
effective for most malaria-affected areas 
in sub-Saharan Africa. This finding 
supports those of previous studies27–29 
showing that parasitic diagnosis had 
the potential to be cost-saving in sub-
Saharan Africa and a simple model that 
indicated the potential for parasitic 
diagnosis to improve health outcomes 
for non-malarial febrile infection in 
epidemic settings.29 Major potential 
health benefits were also identified in a 
population-based model of sub-Saharan 
Africa that found that the introduction 
of a new diagnostic could lead to sig-
nificant reductions in malaria-related 
deaths (assuming that clinical diagnosis 
was less than 100% sensitive) and un-
necessary antimalarial treatments.30
The better health outcomes with 
RDTs relative to presumptive treatment 
do not reflect improved treatment of 
true malaria cases, as the sensitivity of 
RDTs is lower than that of presump-
tive treatment, but rather improved 
treatment of bacterial non-malarial 
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febrile infections, which are assumed 
to be inappropriately treated with ACT 
under presumptive treatment, based on 
current practice. From a cost perspec-
tive, many unnecessary and costly ACT 
treatments could be avoided by the 
use of RDTs, and a substantial number 
of patients with non-malarial febrile ill-
nesses would receive appropriate treat-
ment and be less likely to incur second-
line treatment costs. At a combined best 
estimate of US$ 1.41 for an RDT and 
antibiotic for an adult, the initial costs 
of negative malaria diagnoses are less 
than the current average cost of ACT 
(US$ 1.70).
The analysis suggests that, under 
the assumptions, RDTs would be pref-
erable to microscopy. The RDT strategy 
is always more costly than microscopy 
at the case volumes assumed, but the 
better accuracy of RDTs under current 
routine conditions means that fewer 
DALYs are incurred for patients with 
both malaria and non-malarial illnesses, 
provided prescribers use test results to 
guide their treatment decisions. In large 
facilities, microscopy may offer benefits, 
ignored here, of providing parasite 
counts and diagnosing other diseases. 
However, the costs of improving mi-
croscopy standards to levels similar to 
RDTs in lower-level facilities are likely 
to be significant.
If policy-makers are comfortable 
with 50% certainty, RDTs in rural 
facilities are robustly cost-effective com-
pared with presumptive treatment and 
microscopy under most common preva-
lence scenarios, except when malaria 
prevalence among patients with febrile 
illnesses is relatively high, the cost of 
RDTs is high, adherence to antibiotics 
is low, patients are unlikely to receive 
an antibiotic, a very low proportion of 
non-malarial febrile illnesses are bacte-
rial, or the valuation of health gain is 
very low. If 95% certainty is required, 
the results are more dependent on 
prevalence. At 40% prevalence, we can 
be 95% confident that RDTs are cost-
effective compared with presumptive 
treatment as long as valuation of health 
gain is at least US$ 75 per DALY avert-
ed, RDTs cost less than US$ 2.30 per 
test, antibiotic adherence is greater than 
40%, the percentage of non-malarial fe-
brile illnesses that are bacterial is greater 
than 20%, and the proportion of RDT-
negative cases receiving antibiotics is at 
least 23%.
Models inevitably serve as simpli-
fied approximations of the true nature 
and complexity of behaviours of health-
care providers and patients. In practice, 
treatment-seeking patterns are more 
complex,31,32 and providers often pre-
scribe antimalarials even when tests are 
negative.20,21,33 Cost-effectiveness can be 
substantially reduced where clinicians 
do not adhere to treatment guidelines 
or prescribe according to diagnostic 
results, where inefficient procurement 
leads health facilities to run out of drugs 
or diagnostics frequently, or where qual-
ity assurance for drugs or diagnostics is 
poor.34 Little is known about the impact 
of introducing new diagnostics on pa-
tients’ behaviour, especially on facility 
use and adherence to therapy.
Better data could improve the 
model’s accuracy: the sensitivity and 
specificity of RDTs and microscopy in 
different operational settings, adherence 
to treatment (which affects progression 
to severe disease) and treatment-seeking 
behaviour after treatment failure are all 
of particular importance.
The composition of non-malarial 
febrile illnesses is likely to have a strong 
influence on cost-effectiveness and will 
differ between regions. However, data 
on alternative treatable diagnoses are 
surprisingly scarce and model parameter 
values relied largely on expert opinion. 
In addition, HIV complicates the pic-
ture. We assumed relatively low HIV 
prevalence, but where HIV is more 
common, case fatality rates in indi-
viduals with acute febrile illness could 
be higher, especially for adults with 
non-malarial illness; because this would 
increase the cost-effectiveness of diag-
nostic tools, it does not undermine the 
central conclusion.
The appropriate protocol for the 
treatment of patients testing negative 
for malaria is unclear, and little evidence 
is available on antibiotic prescribing.35 
In our base case we assumed that 100% 
of patients with non-malarial febrile 
Fig. 8. Probability planes showing sensitivity analysis of the cost-effectiveness of RDTs 
compared with presumptive treatment at different valuations of DALYs averted
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Résumé
Rapport coût-efficacité des méthodes de diagnostic du paludisme en Afrique subsaharienne à l’heure des 
polythérapies
Objectif Evaluer le rapport coût-efficacité dans différents 
pays d’Afrique subsaharienne du traitement présomptif, de la 
microscopie classique sur le terrain et des tests diagnostiques 
rapides (TDR) dans le diagnostic du paludisme.
Méthodes Nous avons fait appel à un modèle d’arbre de 
décisions et à une analyse probabiliste de sensibilité, qui ont 
été appliqués aux patients se présentant en ambulatoire dans 
des établissements de soins ruraux avec une présomption de 
paludisme. Nous avons évalué les coûts et les effets du traitement 
à la fois pour les patients positifs aux TDR (en les supposant 
sous traitement par une polythérapie à base d’artémisinine) 
et les patients fébriles négatifs à ces tests (en les supposant 
sous traitement antibiotique). Nous avons considéré que les 
interventions étaient efficientes sous l’angle économique si elles 
étaient moins coûteuses et plus efficaces ou si elles fournissaient un 
coût marginal par année de vie corrigée de l’incapacité évité inférieur 
à US $ 150. Les données ont été extraites de sources publiées et 
non publiées, complétées par des avis d’experts.
Résultats Les TDR se sont révélés efficaces sur le plan 
économique par comparaison avec le traitement présomptif 
jusqu’à des valeurs élevées de la parasitémie due à Plasmodium 
falciparum. Les décideurs peuvent accorder à ce résultat un 
niveau de confiance de 50 % lorsque la prévalence du paludisme 
est inférieure à 81 % et de 95 % lorsque cette prévalence est 
inférieure à 62 %, niveau rarement dépassé dans la pratique. 
Au-dessous de 58 % de prévalence, la probabilité que les TDR 
permettent des économies était supérieure à 50 %. Par rapport à 
la microscopie, les tests avaient une probabilité de plus de 85 % 
d’avoir un bon ratio coût-efficacité sur l’ensemble des niveaux 
de prévalence, en accord avec la meilleure précision qu’on 
s’attend à leur voir fournir en conditions réelles. Ces résultats 
ont résisté à une analyse de sensibilité approfondie. Le rapport 
coût-efficacité des TDR reflétait principalement l’amélioration des 
traitements et des issues des maladies fébriles non palustres, ainsi 
que les économies réalisées sur les coûts des antipaludiques. 
Ces résultats supposaient que les prescripteurs aient utilisé les 
réponses des tests pour guider les décisions thérapeutiques.
Conclusion Les TDR sont en mesure d’avoir un bon rapport coût-
efficacité dans la plupart des régions de l’Afrique subsaharienne. 
Une prise en charge appropriée du paludisme et des maladies 
fébriles non palustres est nécessaire pour tirer un bénéfice 
maximal de ces tests.
Resumen
Costoeficacia de los métodos de diagnóstico de la malaria en el África subsahariana en la era del tratamiento 
combinado
Objetivo Evaluar en diferentes entornos subsaharianos la 
costoeficacia relativa del tratamiento de sospecha, la microscopía 
estándar de campo y las pruebas de diagnóstico rápido (PDR) de 
la malaria.
Métodos Se aplicó un modelo de árbol decisional y un análisis 
de sensibilidad probabilístico a pacientes ambulatorios que 
acudieron a establecimientos de salud rurales con presunta 
malaria. Se consideraron los costos y los efectos tanto para los 
illnesses, and 0% of those with malaria, 
received antibiotics. In reality clinicians 
may target antibiotics to non-malarial 
infections thought more likely to be 
bacterial; this would make RDTs more 
cost-effective. In addition, clinicians 
may prescribe antibiotics to some pa-
tients testing positive for malaria, as in 
the protocol for the Integrated Manage-
ment of Childhood Illness. As many 
patients in sub-Saharan Africa will 
have malaria parasitaemia and bacte-
rial illness, this approach is appropriate 
where clinical suspicion is high.36 Such 
prescribing patterns would reduce the 
incremental effectiveness and costs of 
RDTs relative to presumptive treatment, 
leaving the impact on cost-effectiveness 
uncertain.
The model considers formal outpa-
tient facilities only, although in many 
settings a high proportion of careseekers 
obtain drugs from shops.31,32 Further 
analysis of the cost-effectiveness of 
RDTs at these informal providers is 
warranted. Finally, we have not consid-
ered future benefits from the reduction 
in antimalarial drug pressure, slowing 
the development of antimalarial resis-
tance30 or of increasing antibiotic drug 
pressure through improved specificity 
of malaria diagnosis.
Conclusions
This study demonstrates that in an era 
of ACT, RDTs for malaria have the 
potential to be highly cost-effective 
compared with presumptive treatment 
across most of Africa. This is due as 
much to improved targeting of antibiot-
ics to those who do not have parasites as 
to better targeting of antimalarials. This 
conclusion does, however, depend on 
ensuring accuracy of RDTs in the field 
and use of the tests to guide treatment 
decisions. Efforts to evaluate operational 
RDT use and test the cost-effectiveness 
of interventions to improve clinician ad-
herence to treatment protocols should 
be a priority.  ■
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pacientes positivos en la PDR (suponiendo que se administró 
tratamiento combinado con artemisinina) como para los pacientes 
febriles negativos en la PDR (suponiendo que se administraron 
antibióticos). Se definieron como costoeficaces las intervenciones 
que fueron menos costosas y más eficaces o que habían tenido 
un costo marginal por AVAD (año de vida ajustado en función 
de la discapacidad) ganado de menos de US$ 150. Los datos 
empleados se extrajeron de trabajos publicados o inéditos y se 
complementaron con la opinión de expertos.
Resultados Las PDR fueron costoeficaces en comparación con 
el tratamiento de sospecha hasta valores altos de la prevalencia 
de parasitemia por Plasmodium falciparum. Las instancias 
decisorias pueden confiar con una probabilidad de al menos un 
50% en ese resultado por debajo de una prevalencia de malaria 
del 81%, y del 95% por debajo de una prevalencia del 62%, 
nivel rara vez superado en la práctica. Las PDR tenían una 
probabilidad mayor del 50% de ser costoeficaces por debajo de 
una prevalencia del 58%. En lo que respecta a la microscopía, 
las PDR tenían más de un 85% de probabilidades de ser 
costoeficaces en todos los niveles de prevalencia, lo que 
refleja la mayor exactitud previsible en condiciones reales. Un 
extenso análisis de sensibilidad reveló que los resultados eran 
robustos. La costoeficacia de las PDR se debió principalmente 
al mejor tratamiento y resultados sanitarios conseguidos con las 
dolencias febriles no maláricas, más lo ahorrado en concepto 
de medicamentos antimaláricos. Los resultados dependen del 
supuesto de que los prescriptores tomaron sus decisiones 
terapéuticas en función de los resultados de las pruebas.
Conclusión Las PDR pueden ser costoeficaces en la mayoría 
del África subsahariana, pero para poder sacar el máximo 
provecho de esas pruebas hay que tratar adecuadamente la 
malaria y las enfermedades febriles no maláricas.
صخلم
 ةيقيرفلإا ءارحصلا بونج ةعقاولا قطانلما في فيلاكتلا ءاقل ايرلالما صيخشت قرط ةيلا َّعف
 
ةيفيلوتلا ةجلاعلما صرع في
 ،ةينظلا  ةجلاعلما  مادختسلا  فيلاكتلا  ءاقل  ةيبسنلا  ةيلا َّعفلا  مييقت  :فدهلا
 في  ةعيسرلا  ةيصيخشتلا  تارابتخلااو  ،نياديلما  يرايعلما  يرهجلما  صحفلاو
.ةيقيرفلإا ءارحصلا بونج ةعقاولا قطانلما فلتخم في ايرلالما صيخشت
 ةيساسحلا  ليلحتو  ،تارارقلا  ةرجش  جذونم  مادختساب  انمق  دقل  :ةقيرطلا
 ةيورقلا ةيحصلا قفارلما لىإ ينمداقلا ينيجراخلا ضىرلما لىع قبطلما ،ةيلماتحلاا
 ضىرلما نم لكل ةيلا َّعفلاو فيلاكتلا ليلحت متو .ايرلالماب مهتباصإ في هابتشلال
 ةجلاعلما مادختسا ضاترفاب( ةعيسرلا ةيصيخشتلا تارابتخلال ًاقفو ينيباجيلإا
 ًاقفو  ينيبلسلا  ينمومحلما  ضىرلماو  ،)يننسيماطرلأا  لىع  ةزكترلما  ةيفيلوتلا
 فَّرَعُتو .)يويحلا داضلماب ةجلاعلما ضاترفاب( ةعيسرلا ةيصيخشتلا تارابتخلال
 وأ ،ثركأ اهتيلا َّعفو ،لقأ اهتفلكت تناك اذإ ،فيلاكتلا ءاقل اهتيلاعفب تلاخدتلا
 باستحاب ةححصلما رمعلا تاونس نم ةنس لكل ةيمكاترلا اهتفلكت نوكت نأ
 ت َّدِمُتسا دقو .ًايكيرمأ ًارلاود 150 نم لقأ اهيدافت نكيم يتلا زجعلا تاونس
.ءابرخلا ءارآ اهديؤت يتلاو ،ةروشنلما يرغو ةروشنلما رداصلما نم تايطعلما
 ءاقل  ةيلاع  ةيلاعفب  ةعيسرلا  ةيصيخشتلا  تارابتخلاا  زيمتت  :تادوجولما
 تاجرد لىإ لىعلأا اهدح في لصت يتلا ،ةَّينظلا ةجلاعلما عم ةنراقلماب فيلاكتلا
 نكيم  َّمـث  نمو  .مدلا  في  ةيلجنلما  تاروصتلما  نارود  نم  ةعفترلما  راشتنلاا
 امدنع جئاتنلا هذه نم لقلأا لىع %50 ةبسنب ينقثاو اونوكي نأ رارقلا عانصل
 نع راشتنلاا لقي امدنع %95 ةبسنب ينقثاوو ،%81 نع ايرلالما راشتنا لقي
 .عقاولا ضرأ لىع ةيلمعلا تاسرمالما في اهزواجت ردني تلا َّدعم يهو .%62
 %50 زواجتت ةبسنب فيلاكتلا رفوت نأ اهنكيم عيسرلا صيخشتلا تارابتخاف
 زيمتت  ،يرهجلما  صحفلاب  ةنراقلمابو  .%58  نم  لقلأا  راشتنلاا  تلااح  في
 زواجتت  ةبسنب  فيلاكتلا  ءاقل  بركأ  ةيلاعفب  ةعيسرلا  ةيصيخشتلا  تارابتخلاا
 ةعقوتلما ةقدلا نم لىعأ ةجرد سكعي مام ،راشتنلاا تايوتسم لك في %85
 ليلاحتلل ًاقفو يفكي ابم ةيوق جئاتنلا تءاج دقو .ةيقيقحلا ةايحلا فورظ في
 ءاقل  ةعيسرلا  ةيصيخشتلا  تارابتخلاا  ةيلاعف  تسكعو  .ةيساسحلل  ةفثكلما
 ىرخلأا  ةيومحلا  ضارملأل  ةيحصلا  لئاصحلاو  ةجلاعلما  ن ُّسَحت  ،فيلاكتلا
 .ايرلاملل ةداضلما ةيودلأا فيلاكت يرفوت نع ًلاضف ،ايرلالما نع مجنت لا يتلا
 جئاتن لىع اودمتعا ةجلاعلما يفصاو نأ ،هدافم ضاترفا لىع جئاتنلا تزكتراو
 .ةجلاعلما تارارق هيجوت في رابتخلاا
 ءاقل  ةيلا َّعفلا  قيقحت  ةعيسرلا  ةيصيخشتلا  تارابتخلاا  رودقبم  :جاتنتسلاا
 نمو .ةيقيرفلأا  ءارحصلا  بونج ةعقاولا  قطانلما  ءازجأ مظعم في فيلاكتلا
 ايرلالما نع ةمجانلا ءاوس ةيومحلا ضارملأل ةئملالما ةجلاعلما لىع يغبني َّمـث
 هذه نم ةدافتسا صىقأ قيقحت ،ايرلالما نع مجنت لا يتلا ىرخلأا ضارملأا وأ
.تارابتخلاا
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